Stealth BioTherapeutics Inc.
Stealth BioTherapeutics Inc. develops novel mitochondria-targeted therapies for diseases with clear, unmet medical needs. The company's first clinical candidate is Elamipretide, a compound that targets the mitochondria to treat ischemia reperfusion injury, a common complication of interventional procedures for acute myocardial infarction. Several completed clinical trials evaluated the clinical safety and pharmacokinetics of Elamipretide in healthy and renally impaired volunteers. Stealth BioTherapeutics is now initiating a multinational Phase II clinical trial.
Stealth BioTherapeutics' foundational technology is licensed from Cornell University. The company has continued research interactions with the university.